{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166104996",
    "name" : "CPIC Guideline for codeine and CYP2D6",
    "descriptiveVideoId" : "wzNavTUg9KA",
    "history" : [ {
      "id" : 1183699759,
      "date" : "2011-12-28T00:00:00-08:00",
      "type" : "create",
      "version" : 0
    }, {
      "id" : 1183703037,
      "date" : "2014-01-24T00:00:00-08:00",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1447983994,
      "date" : "2016-05-05T12:28:51.930-07:00",
      "description" : "corrected error in guideline link",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1448604644,
      "date" : "2017-03-15T00:00:00-07:00",
      "description" : "Updated extended dosing guidelines",
      "type" : "update",
      "version" : 0
    } ],
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA449088",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA449088",
      "name" : "codeine",
      "version" : 10
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA128",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA128",
      "symbol" : "CYP2D6",
      "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6",
      "version" : 7887
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447982022,
      "externalLinks" : [ ],
      "html" : "<p>Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific codeine dose is warranted for CYP2D6 extensive and intermediate metabolizers.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific codeine dose is warranted for CYP2D6 extensive and intermediate metabolizers.",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 0
    },
    "summaryVideoId" : "HjhrN_YDe6w",
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447982021,
      "externalLinks" : [ "https://cpicpgx.org/", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-CYP2D6%20allele%20frequency%20table.xlsx", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-CYP2D6%20allele%20table%20and%20legend.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-CYP2D6%20allele%20frequency%20table%20(R2).xlsx", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-CYP2D6%20allele%20table%20and%20legend%20(R2).pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010.pdf" ],
      "html" : "<h3 id=\"august-2015-update-on-pharmgkb\">August 2015 Update on PharmGKB</h3>\n<ul>\n<li>Supplemental table S3 (Association between allelic variants and CYP2D6 enzyme activity) was updated with Supplemental table S2 from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors (2015 Supplement) PMID: 25974703. The table is an updated version including additions to functional status and additional alleles.</li>\n</ul>\n<h3 id=\"april-2014-update\">April 2014 Update</h3>\n<p><em>Advance online publication January 2014.</em></p>\n<ul>\n<li>The 2014 update of CPIC guidelines regarding CYP2D6 and codeine have been published in Clinical Pharmacology and Therapeutics. Literature up to August 2013 was reviewed. <strong>The update addresses the FDA warning regarding codeine use in children following tonsillectomy with or without adenoidectomy, pediatric considerations, and additional considerations for use of alternative opioids metabolized by CYP2D6</strong>. In addition, supplemental information was updated.</li>\n<li>Excerpts from the 2014 guideline update:\n<ul>\n<li>&quot;<em>CYP2D6</em> genotype is expected to be equally reliable for inferring phenotype from genotype in children as in adults. Codeine is not recommended in children less than 2 years of age but presumably would carry additional dangers in neonates and young children who are ultrarapid metabolizers.&quot;</li>\n<li>&quot;Caution should be used when prescribing codeine to a breastfeeding woman with an ultrarapid metabolizer status.&quot;</li>\n<li>&quot;In February 2013, the FDA announced its strongest and new black box warning against codeine use to manage postoperative pain in children following tonsillectomy with or without adenoidectomy. This warning was in response to further FDA review of the codeine-related deaths and serious adverse drug reactions. The FDA warning is applicable to all children undergoing tonsillectomy with or without adenoidectomy irrespective of their obstructive sleep apnea status or CYP2D6 genotype/phenotype.&quot;</li>\n</ul>\n</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>pediatric patients</li>\n<li>adult patients</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2014%2F24458010.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2014%2F24458010-supplement.pdf\" target=\"_blank\">2014 supplement</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2014%2F24458010-CYP2D6%2520allele%2520table%2520and%2520legend%2520%28R2%29.pdf\" target=\"_blank\">CYP2D6 frequency table legend (R2)</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2014%2F24458010-CYP2D6%2520allele%2520frequency%2520table%2520%28R2%29.xlsx\" target=\"_blank\">CYP2D6 frequency table (R2)</a></li>\n</ul>\n</li>\n</ul>\n<h4 id=\"table-1-recommended-dosing-of-codeine-by-cyp2d6-phenotype\">Table 1: Recommended dosing of codeine by CYP2D6 Phenotype</h4>\n<p><em>Adapted from Tables 1 and 2 of the 2014 guideline update manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Likely phenotype.<sup>a</sup></th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for codeine metabolism</th><th>Recommendations for codeine therapy.<sup>b</sup></th><th>Classification of recommendation for codeine therapy</th><th>Considerations for alternative opioids</th></tr>\n</thead>\n<tbody>\n<tr><td>Ultrarapid metabolizer (~1-2% of patients)</td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased formation of morphine following codeine administration, leading to higher risk of toxicity</td><td>Avoid codeine use due to potential for toxicity.</td><td>Strong</td><td>Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity.<sup>d,e</sup></td></tr>\n<tr><td>Extensive metabolizer (~77-92% of patients)</td><td>1.0-2.0.<sup>c</sup></td><td>An individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele</td><td>*1/*1, *1/*2, *2/*2, *1/*41, *1/*4, *2/*5, *10/*10</td><td>Normal morphine formation</td><td>Use label recommended age- or weight-specific dosing.</td><td>Strong</td><td></td></tr>\n<tr><td>Intermediate metabolizer (~2-11% of patients)</td><td>0.5.<sup>c</sup></td><td>An individual carrying one reduced and one nonfunctional allele</td><td>*4/*10, *5/*41</td><td>Reduced morphine formation</td><td>Use label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid.</td><td>Moderate</td><td>Monitor tramadol use for response.</td></tr>\n<tr><td>Poor metabolizer (~5-10% of patients)</td><td>0</td><td>An individual carrying no functional alleles</td><td>*4/*4, *4/*5, *5/*5, *4/*6</td><td>Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief</td><td>Avoid codeine use due to lack of efficacy.</td><td>Strong</td><td>Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided.<sup>d,e</sup></td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Frequency estimates are based on data from Caucasians and may differ substantially for other ethnicities. See 2014 supplement above for estimates of phenotype frequencies among different ethnic/geographic groups.</p>\n<p><sup>b</sup> Rating scheme is described in supplemental material - see 2014 update above.</p>\n<p><sup>c</sup> Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as extensive metabolizers.  Classifying patients with an activity score of 1.0 as extensive metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients [Article:<a href=\"/pmid/19395173\">19395173</a>].</p>\n<p><sup>d</sup> There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery.  Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable (see 2014 update above).</p>\n<p><sup>e</sup> Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</p>\n<h3 id=\"february-2012\">February 2012</h3>\n<p><em>Advance online publication Dec 2011.</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for codeine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2F\" target=\"_blank\">(CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>pediatric patients</li>\n<li>adult patients</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2012%2F22205192.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2012%2F22205192-supplement.pdf\" target=\"_blank\">2012 supplement</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2012%2F22205192-CYP2D6%2520allele%2520table%2520and%2520legend.pdf\" target=\"_blank\">CYP2D6 frequency table legend (R2)</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fcodeine%2F2012%2F22205192-CYP2D6%2520allele%2520frequency%2520table.xlsx\" target=\"_blank\">CYP2D6 frequency table</a></li>\n</ul>\n</li>\n</ul>\n",
      "internalLinks" : [ ],
      "markdown" : "##  August 2015 Update on PharmGKB\r\n- Supplemental table S3 (Association between allelic variants and CYP2D6 enzyme activity) was updated with Supplemental table S2 from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors (2015 Supplement) PMID: 25974703. The table is an updated version including additions to functional status and additional alleles. \r\n\r\n## April 2014 Update\r\n\r\n_Advance online publication January 2014._\r\n\r\n- The 2014 update of CPIC guidelines regarding CYP2D6 and codeine have been published in Clinical Pharmacology and Therapeutics. Literature up to August 2013 was reviewed. __The update addresses the FDA warning regarding codeine use in children following tonsillectomy with or without adenoidectomy, pediatric considerations, and additional considerations for use of alternative opioids metabolized by CYP2D6__. In addition, supplemental information was updated.\r\n- Excerpts from the 2014 guideline update: \r\n    - \"_CYP2D6_ genotype is expected to be equally reliable for inferring phenotype from genotype in children as in adults. Codeine is not recommended in children less than 2 years of age but presumably would carry additional dangers in neonates and young children who are ultrarapid metabolizers.\"\r\n    - \"Caution should be used when prescribing codeine to a breastfeeding woman with an ultrarapid metabolizer status.\"\r\n    - \"In February 2013, the FDA announced its strongest and new black box warning against codeine use to manage postoperative pain in children following tonsillectomy with or without adenoidectomy. This warning was in response to further FDA review of the codeine-related deaths and serious adverse drug reactions. The FDA warning is applicable to all children undergoing tonsillectomy with or without adenoidectomy irrespective of their obstructive sleep apnea status or CYP2D6 genotype/phenotype.\"\r\n- These guidelines are applicable to:\r\n  - pediatric patients \r\n  - adult patients\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update ](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010.pdf) \r\n  - [2014 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-supplement.pdf)  \r\n  - [CYP2D6 frequency table legend (R2)](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-CYP2D6%20allele%20table%20and%20legend%20(R2).pdf)\r\n  - [CYP2D6 frequency table (R2)](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2014/24458010-CYP2D6%20allele%20frequency%20table%20(R2).xlsx)\r\n\r\n### Table 1: Recommended dosing of codeine by CYP2D6 Phenotype\r\n\r\n_Adapted from Tables 1 and 2 of the 2014 guideline update manuscript._\r\n\r\n| Likely phenotype.^a^ | Activity score | Genotypes | Examples of diplotypes | Implications for codeine metabolism | Recommendations for codeine therapy.^b^ | Classification of recommendation for codeine therapy |Considerations for alternative opioids|\r\n| --- | --- | --- | --- | --- | --- | --- | --- |\r\n| Ultrarapid metabolizer (~1-2% of patients) | >2.0 | An individual carrying more than two copies of functional alleles | *1/*1xN, *1/*2xN | Increased formation of morphine following codeine administration, leading to higher risk of toxicity | Avoid codeine use due to potential for toxicity.| Strong |Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity.^d,e^|\r\n| Extensive metabolizer (~77-92% of patients) | 1.0-2.0.^c^ | An individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele | *1/*1, *1/*2, *2/*2, *1/*41, *1/*4, *2/*5, *10/*10 | Normal morphine formation | Use label recommended age- or weight-specific dosing. | Strong |  |\r\n| Intermediate metabolizer (~2-11% of patients) | 0.5.^c^ | An individual carrying one reduced and one nonfunctional allele | *4/*10, *5/*41 | Reduced morphine formation | Use label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid.|   Moderate | Monitor tramadol use for response.|\r\n| Poor metabolizer (~5-10% of patients) | 0 | An individual carrying no functional alleles | *4/*4, *4/*5, *5/*5, *4/*6  | Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief | Avoid codeine use due to lack of efficacy.  | Strong |Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided.^d,e^|\r\n\r\n^a^ Frequency estimates are based on data from Caucasians and may differ substantially for other ethnicities. See 2014 supplement above for estimates of phenotype frequencies among different ethnic/geographic groups.\r\n\r\n^b^ Rating scheme is described in supplemental material - see 2014 update above. \r\n\r\n^c^ Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as extensive metabolizers.  Classifying patients with an activity score of 1.0 as extensive metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients [PMID: 19395173].\r\n\r\n^d^ There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery.  Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable (see 2014 update above).\r\n\r\n^e^ Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.\r\n\r\n## February 2012 \r\n\r\n_Advance online publication Dec 2011._\r\n\r\n- Guidelines regarding the use of pharmacogenomic tests in dosing for codeine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](https://cpicpgx.org/).\r\n- These guidelines are applicable to:\r\n  - pediatric patients \r\n  - adult patients\r\n- Download and read: \r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192.pdf)\r\n  - [2012 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-supplement.pdf)\r\n  - [CYP2D6 frequency table legend (R2)](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-CYP2D6%20allele%20table%20and%20legend.pdf)\r\n  - [CYP2D6 frequency table](https://github.com/PharmGKB/cpic-guidelines/raw/master/codeine/2012/22205192-CYP2D6%20allele%20frequency%20table.xlsx)",
      "pmids" : [ "19395173" ],
      "relatedObjects" : [ ],
      "version" : 8
    },
    "version" : 32,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983494,"resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-codeine-and-cyp2d6%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128773",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128773",
    "name" : "Normal Metabolizer",
    "annotations" : [ {
      "id" : 1445562861,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986482,
        "externalLinks" : [ ],
        "html" : "<p>1.0-2.0</p>\n<p><em>Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as normal metabolizers. Classifying patients with an activity score of 1.0 as normal metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients [Article:19395173].</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "1.0-2.0 \r\n\r\n_Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as normal metabolizers. Classifying patients with an activity score of 1.0 as normal metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients \\[Article:19395173]._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501924",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501924,
        "resource" : "Guideline Tags",
        "term" : "Activity Score",
        "termId" : "guidelineTags:981501924",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562863,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986484,
        "externalLinks" : [ ],
        "html" : "<p>Normal morphine formation</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal morphine formation",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562864,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986485,
        "externalLinks" : [ ],
        "html" : "<p>Normal Metabolizer</p>\n<p><em>CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [Article:<a href=\"/pmid/27441996\">27441996</a>] for drug metabolizing enzymes.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal Metabolizer\r\n\r\n_CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [PMID: 27441996] for drug metabolizing enzymes._",
        "pmids" : [ "27441996" ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562862,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986483,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562865,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986486,
        "externalLinks" : [ ],
        "html" : "<p>Use label recommended age- or weight-specific dosing.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Use label recommended age- or weight-specific dosing.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "CYP2D6:Decreased Function/Decreased Function", "CYP2D6:Decreased Function/Normal Function", "CYP2D6:No Function/Normal Function", "CYP2D6:Normal Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 10
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128774",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128774",
    "name" : "Intermediate Metabolizer",
    "annotations" : [ {
      "id" : 1445562866,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986487,
        "externalLinks" : [ ],
        "html" : "<p>0.5</p>\n",
        "internalLinks" : [ ],
        "markdown" : "0.5",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501924",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501924,
        "resource" : "Guideline Tags",
        "term" : "Activity Score",
        "termId" : "guidelineTags:981501924",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562868,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986489,
        "externalLinks" : [ ],
        "html" : "<p>Reduced morphine formation</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Reduced morphine formation",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562869,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986490,
        "externalLinks" : [ ],
        "html" : "<p>Intermediate Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Intermediate Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562867,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986488,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one reduced and one nonfunctional allele</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one reduced and one nonfunctional allele",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562870,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986491,
        "externalLinks" : [ ],
        "html" : "<p>Use label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid.</p>\n<p>Considerations for alternative opioids: Monitor tramadol use for response.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Use label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid. \n\nConsiderations for alternative opioids: Monitor tramadol use for response.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "CYP2D6:Decreased Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602496",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602496,
      "resource" : "Prescribing Change",
      "term" : "Possibly",
      "termId" : "rxChange:1448602496",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "resource" : "Guideline Strength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931",
      "version" : 0
    },
    "version" : 10
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128775",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128775",
    "name" : "Poor Metabolizer",
    "annotations" : [ {
      "id" : 1445562871,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986492,
        "externalLinks" : [ ],
        "html" : "<p>0</p>\n",
        "internalLinks" : [ ],
        "markdown" : "0",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501924",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501924,
        "resource" : "Guideline Tags",
        "term" : "Activity Score",
        "termId" : "guidelineTags:981501924",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562873,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986494,
        "externalLinks" : [ ],
        "html" : "<p>Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562874,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986495,
        "externalLinks" : [ ],
        "html" : "<p>Poor Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Poor Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562872,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986493,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying no functional alleles</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying no functional alleles",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562875,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986496,
        "externalLinks" : [ ],
        "html" : "<p>Avoid codeine use due to lack of efficacy.</p>\n<p><em>Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Avoid codeine use due to lack of efficacy. \r\n\r\n_Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "CYP2D6:No Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 10
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128776",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128776",
    "name" : "Ultrarapid Metabolizer or Normal Metabolizer",
    "annotations" : [ {
      "id" : 1445562881,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986741,
        "externalLinks" : [ ],
        "html" : "<p>2 - For the combination of a no function allele with a duplicated normal function allele.</p>\n<p>&gt;2 - For the combination of a no function allele and more than two copies of a normal function allele.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "2 - For the combination of a no function allele with a duplicated normal function allele.\r\n\r\n\\>2 - For the combination of a no function allele and more than two copies of a normal function allele.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501924",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501924,
        "resource" : "Guideline Tags",
        "term" : "Activity Score",
        "termId" : "guidelineTags:981501924",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562883,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986743,
        "externalLinks" : [ ],
        "html" : "<p><strong>For the combination of a no function allele with a duplicated normal function allele:</strong></p>\n<p>Normal morphine formation</p>\n<p><strong>For the combination of a no function allele and more than two copies of a normal function allele:</strong></p>\n<p>Increased formation of morphine following codeine administration, leading to higher risk of toxicity</p>\n",
        "internalLinks" : [ ],
        "markdown" : "__For the combination of a no function allele with a duplicated normal function allele:__\n\nNormal morphine formation\n\n__For the combination of a no function allele and more than two copies of a normal function allele:__\n\nIncreased formation of morphine following codeine administration, leading to higher risk of toxicity",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562885,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986744,
        "externalLinks" : [ ],
        "html" : "<p><strong>For the combination of a no function allele with a duplicated normal function allele:</strong></p>\n<p>Normal Metabolizer</p>\n<p><em>CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [Article:<a href=\"/pmid/27441996\">27441996</a>] for drug metabolizing enzymes.</em></p>\n<p><strong>For the combination of a no function allele and more than two copies of a normal function allele:</strong></p>\n<p>Ultrarapid Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "__For the combination of a no function allele with a duplicated normal function allele:__\r\n\r\nNormal Metabolizer\r\n\r\n_CPIC Term Standardization Project recommended replacing the term ‘extensive’ metabolizer with ‘normal’ metabolizer [PMID: 27441996] for drug metabolizing enzymes._ \r\n\r\n__For the combination of a no function allele and more than two copies of a normal function allele:__\r\n\r\nUltrarapid Metabolizer",
        "pmids" : [ "27441996" ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562882,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986742,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying a no function allele and a duplicated normal function allele or a no function allele and more than two copies of a normal function allele.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying a no function allele and a duplicated normal function allele or a no function allele and more than two copies of a normal function allele.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562886,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986745,
        "externalLinks" : [ ],
        "html" : "<p><strong>For the combination of a no function allele with a duplicated normal function allele:</strong></p>\n<p>Use label recommended age- or weight-specific dosing.</p>\n<p><strong>For the combination of a no function allele and more than two copies of a normal function allele:</strong></p>\n<p>Avoid codeine use due to potential for toxicity.</p>\n<p><em>Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "__For the combination of a no function allele with a duplicated normal function allele:__\r\n\r\nUse label recommended age- or weight-specific dosing.\r\n\r\n__For the combination of a no function allele and more than two copies of a normal function allele:__\r\n\r\nAvoid codeine use due to potential for toxicity. \r\n\r\n_Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "CYP2D6:Increased Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602496",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602496,
      "resource" : "Prescribing Change",
      "term" : "Possibly",
      "termId" : "rxChange:1448602496",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 10
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128772",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128772",
    "name" : "Ultrarapid Metabolizer",
    "annotations" : [ {
      "id" : 1445562857,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986478,
        "externalLinks" : [ ],
        "html" : "<p>&gt;2.0</p>\n",
        "internalLinks" : [ ],
        "markdown" : "\\>2.0",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501924",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501924,
        "resource" : "Guideline Tags",
        "term" : "Activity Score",
        "termId" : "guidelineTags:981501924",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562858,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986479,
        "externalLinks" : [ ],
        "html" : "<p>Increased formation of morphine following codeine administration, leading to higher risk of toxicity</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Increased formation of morphine following codeine administration, leading to higher risk of toxicity",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562859,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986480,
        "externalLinks" : [ ],
        "html" : "<p>Ultrarapid Metabolizer</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Ultrarapid Metabolizer",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 7
    }, {
      "id" : 1445562856,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986477,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying more than two copies of functional alleles</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying more than two copies of functional alleles",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445562860,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986481,
        "externalLinks" : [ ],
        "html" : "<p>Avoid codeine use due to potential for toxicity.</p>\n<p><em>Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Avoid codeine use due to potential for toxicity. \r\n\r\n_Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 7
    } ],
    "genePhenotypes" : [ "CYP2D6:Decreased Function/Increased Function", "CYP2D6:Increased Function/Increased Function", "CYP2D6:Increased Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 10
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166162350",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166162350",
    "name" : "Indeterminate",
    "annotations" : [ {
      "id" : 1448531444,
      "history" : [ ],
      "markdown" : {
        "id" : 1448531443,
        "externalLinks" : [ ],
        "html" : "<p>N/A</p>\n",
        "internalLinks" : [ ],
        "markdown" : "N/A",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448531446,
      "history" : [ ],
      "markdown" : {
        "id" : 1448531445,
        "externalLinks" : [ ],
        "html" : "<p>Indeterminate</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Indeterminate",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448531442,
      "history" : [ ],
      "markdown" : {
        "id" : 1448531441,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one or two unknown/uncertain function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one or two unknown/uncertain function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1448531448,
      "history" : [ ],
      "markdown" : {
        "id" : 1448531447,
        "externalLinks" : [ ],
        "html" : "<p>This guideline does not contain recommendations for this allele combination.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "This guideline does not contain recommendations for this allele combination.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 0
    } ],
    "genePhenotypes" : [ "CYP2D6:Decreased Function/Unknown or Uncertain Function", "CYP2D6:Increased Function/Unknown or Uncertain Function", "CYP2D6:No Function/Unknown or Uncertain Function", "CYP2D6:Normal Function/Unknown or Uncertain Function", "CYP2D6:Unknown or Uncertain Function/Unknown or Uncertain Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104996",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104996",
      "name" : "CPIC Guideline for codeine and CYP2D6",
      "version" : 32
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "version" : 1
  } ],
  "genePhenotypes" : {
    "CYP2D6" : {
      "*1" : "Normal Function",
      "*1xN" : "Increased Function",
      "*2" : "Normal Function",
      "*2xN" : "Increased Function",
      "*3" : "No Function",
      "*3xN" : "No Function",
      "*4" : "No Function",
      "*4xN" : "No Function",
      "*5" : "No Function",
      "*6" : "No Function",
      "*6xN" : "No Function",
      "*7" : "No Function",
      "*8" : "No Function",
      "*9" : "Decreased Function",
      "*9x2" : "Normal Function",
      "*10" : "Decreased Function",
      "*10x2" : "Normal Function",
      "*11" : "No Function",
      "*12" : "No Function",
      "*13" : "No Function",
      "*14A" : "No Function",
      "*14B" : "Decreased Function",
      "*15" : "No Function",
      "*17" : "Decreased Function",
      "*17x2" : "Normal Function",
      "*18" : "No Function",
      "*19" : "No Function",
      "*20" : "No Function",
      "*21" : "No Function",
      "*22" : "Unknown or Uncertain Function",
      "*23" : "Unknown or Uncertain Function",
      "*24" : "Unknown or Uncertain Function",
      "*25" : "Unknown or Uncertain Function",
      "*26" : "Unknown or Uncertain Function",
      "*27" : "Normal Function",
      "*28" : "Unknown or Uncertain Function",
      "*29" : "Decreased Function",
      "*29x2" : "Normal Function",
      "*30" : "Unknown or Uncertain Function",
      "*31" : "No Function",
      "*32" : "Unknown or Uncertain Function",
      "*33" : "Normal Function",
      "*34" : "Normal Function",
      "*35" : "Normal Function",
      "*35xN" : "Increased Function",
      "*36" : "No Function",
      "*36xN" : "No Function",
      "*37" : "Unknown or Uncertain Function",
      "*38" : "No Function",
      "*39" : "Normal Function",
      "*40" : "No Function",
      "*41" : "Decreased Function",
      "*41x2" : "Normal Function",
      "*42" : "No Function",
      "*43" : "Unknown or Uncertain Function",
      "*44" : "No Function",
      "*45" : "Normal Function",
      "*45xN" : "Increased Function",
      "*46" : "Normal Function",
      "*47" : "No Function",
      "*48" : "Normal Function",
      "*49" : "Decreased Function",
      "*50" : "Decreased Function",
      "*51" : "No Function",
      "*52" : "Unknown or Uncertain Function",
      "*53" : "Normal Function",
      "*54" : "Decreased Function",
      "*55" : "Decreased Function",
      "*56" : "No Function",
      "*57" : "No Function",
      "*58" : "Unknown or Uncertain Function",
      "*59" : "Decreased Function",
      "*60" : "Unknown or Uncertain Function",
      "*61" : "Unknown or Uncertain Function",
      "*62" : "No Function",
      "*63" : "Unknown or Uncertain Function",
      "*64" : "Unknown or Uncertain Function",
      "*65" : "Unknown or Uncertain Function",
      "*68" : "No Function",
      "*69" : "No Function",
      "*70" : "Unknown or Uncertain Function",
      "*71" : "Unknown or Uncertain Function",
      "*72" : "Decreased Function",
      "*73" : "Unknown or Uncertain Function",
      "*74" : "Unknown or Uncertain Function",
      "*75" : "Unknown or Uncertain Function",
      "*81" : "Unknown or Uncertain Function",
      "*82" : "Unknown or Uncertain Function",
      "*83" : "Unknown or Uncertain Function",
      "*84" : "Unknown or Uncertain Function",
      "*85" : "Unknown or Uncertain Function",
      "*86" : "Unknown or Uncertain Function",
      "*87" : "Unknown or Uncertain Function",
      "*88" : "Unknown or Uncertain Function",
      "*89" : "Unknown or Uncertain Function",
      "*90" : "Unknown or Uncertain Function",
      "*91" : "Unknown or Uncertain Function",
      "*92" : "No Function",
      "*93" : "Unknown or Uncertain Function",
      "*94" : "Unknown or Uncertain Function",
      "*95" : "Unknown or Uncertain Function",
      "*96" : "Unknown or Uncertain Function",
      "*97" : "Unknown or Uncertain Function",
      "*98" : "Unknown or Uncertain Function",
      "*100" : "No Function",
      "*101" : "No Function",
      "*102" : "Unknown or Uncertain Function",
      "*103" : "Unknown or Uncertain Function",
      "*104" : "Unknown or Uncertain Function",
      "*105" : "Unknown or Uncertain Function",
      "*107" : "Unknown or Uncertain Function",
      "*108" : "Unknown or Uncertain Function",
      "*109" : "Unknown or Uncertain Function"
    }
  },
  "citations" : [ {
    "@id" : "https://api.pharmgkb.org/data/literature/24458010",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15069654,
    "resourceId" : "24458010",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update",
    "authors" : [ "Crews Kristine R", "Gaedigk Andrea", "Dunnenberger Henry M", "Leeder J Steve", "Klein Teri E", "Caudle Kelly E", "Haidar Cyrine E", "Shen Danny D", "Callaghan John T", "Sadhasivam Senthilkumar", "Prows Cynthia A", "Kharasch Evan D", "Skaar Todd C" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 1,
    "nonHuman" : false,
    "pubDate" : "2014-01-01T00:00:00-08:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/24458010",
    "sentences" : [ {
      "location" : "title",
      "id" : 15069655,
      "text" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update",
      "sentenceIndex" : 0
    }, {
      "location" : "abstract",
      "id" : 15069656,
      "text" : "Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity.",
      "sentenceIndex" : 1
    }, {
      "location" : "abstract",
      "id" : 15069657,
      "text" : "Polymorphisms are a major cause of CYP2D6 variability.",
      "sentenceIndex" : 2
    }, {
      "location" : "abstract",
      "id" : 15069658,
      "text" : "We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype.",
      "sentenceIndex" : 3
    }, {
      "location" : "abstract",
      "id" : 15069659,
      "text" : "This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.",
      "sentenceIndex" : 4
    }, {
      "location" : "abstract",
      "id" : 15069660,
      "text" : "(1)Clinical Pharmacology & Therapeutics (2014); accepted article preview online 23 January 2014 doi:10.1038/clpt.2013.254.",
      "sentenceIndex" : 5
    } ],
    "summary" : "Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy. (1)Clinical Pharmacology & Therapeutics (2014); accepted article preview online 23 January 2014 doi:10.1038/clpt.2013.254.",
    "type" : "article",
    "version" : 1,
    "year" : 2014
  }, {
    "@id" : "https://api.pharmgkb.org/data/literature/22205192",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 14821790,
    "resourceId" : "22205192",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype",
    "authors" : [ "Crews K R", "Gaedigk A", "Dunnenberger H M", "Klein T E", "Shen D D", "Callaghan J T", "Kharasch E D", "Skaar T C" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 12,
    "nonHuman" : false,
    "pubDate" : "2011-12-01T00:00:00-08:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/22205192",
    "sentences" : [ {
      "location" : "title",
      "id" : 14821791,
      "text" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype",
      "sentenceIndex" : 0
    } ],
    "type" : "article",
    "version" : 1,
    "year" : 2011
  } ]
}